Santhera Pharmaceuticals Holding AG
SANN
Clasificación en acciones
#16116
Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company,... Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and sells medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the Europe, North America, and Asia. The company’s lead pipeline candidate includes Vamorolone, which is developed for the treatments of Duchenne muscular dystrophy. Its clinical stage pipeline also comprises Lonodelestat for the treatment of cystic fibrosis and other neutrophilic pulmonary diseases. Santhera Pharmaceuticals Holding AG was founded in 2004 and is based in Pratteln, Switzerland.
Precio por acción
$19.07
Capitalización bursátil
$291.75M
Cambio (1 día)
-0.27%
Cambio (1 año)
48.61%
País
CH
Comercio Santhera Pharmaceuticals Holding AG (SANN)
Categoría
Healthcare
Ratio P/S de Santhera Pharmaceuticals Holding AG (SANN)
Ratio P/S al 2026 TTM: 0
Según los informes financieros más recientes y el precio de las acciones de Santhera Pharmaceuticals Holding AG, el ratio P/S actual (TTM) es 0. Al final de 2026, el ratio P/S era 0.
Historial del ratio P/S de Santhera Pharmaceuticals Holding AG desde 2026 hasta 2026
Ratio P/S al final de cada año
| Año | Ratio P/S | Cambiar |
|---|---|---|
| Not enough data for the provided dates. | ||
Ratio P/S de empresas similares o competidoras
| Empresa | Ratio P/S | Diferencia del ratio P/S | País |
|---|---|---|---|
| 10.02 | - |
US
|
|
| 40.55 | - |
US
|
|
| 3.96 | - |
AU
|
|
| - | - |
CH
|
|
| 10.15 | - |
NL
|
